Stay updated with breaking news from Yang Qinping. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Suzhou, August 22, 2023 - Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company...
/PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and...
Suzhou, April 14, 2023 - Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has... | April 14, 2023
/PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and...
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first dosing in its phase III clinical trial of KX-826 ("pyrilutamide") in China for the treatment of male androgenetic alopecia (AGA) patients on December 31, 2021. KX-826 is the first androgen receptor (AR) antagonist that has entered the phase III clinical trial for AGA treatment in China and globally. - Click here if this is your press release! - eTurboNews | Trends | Travel News